0001437749-24-018931.txt : 20240531
0001437749-24-018931.hdr.sgml : 20240531
20240531165608
ACCESSION NUMBER: 0001437749-24-018931
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240529
FILED AS OF DATE: 20240531
DATE AS OF CHANGE: 20240531
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cittadine Andrew
CENTRAL INDEX KEY: 0001863624
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39070
FILM NUMBER: 241010587
MAIL ADDRESS:
STREET 1: C/O 1000 SKOKIE BLVD SUITE 350
CITY: WILMETTE
STATE: IL
ZIP: 60091
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Monopar Therapeutics
CENTRAL INDEX KEY: 0001645469
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 320463781
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1000 SKOKIE BLVD SUITE 350
CITY: WILMETTE
STATE: IL
ZIP: 60091
BUSINESS PHONE: 8473880349
MAIL ADDRESS:
STREET 1: 1000 SKOKIE BLVD SUITE 350
CITY: WILMETTE
STATE: IL
ZIP: 60091
4
1
rdgdoc.xml
FORM 4
X0508
4
2024-05-29
0001645469
Monopar Therapeutics
MNPR
0001863624
Cittadine Andrew
1000 SKOKIE BLVD SUITE 350
WILMETTE
IL
60091
1
Chief Operating Officer
0
Common Stock
2024-05-29
4
P
0
12000
0.6369
A
69624
D
Common Stock
2024-05-30
4
P
0
12000
0.6397
A
81624
D
Common Stock
2024-05-31
4
P
0
12000
0.6443
A
93624
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.629 to $0.637, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.629 to $0.64, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.61 to $0.6502, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.
/s/ Kim R Tsuchimoto, Attorney-in-fact
2024-05-31